在肺移植后的初级移植功能障碍上,全基因介质细胞 stromal 细胞治疗
Abbas Ali Qayyum1,2,3, Thomas Kromann Lund4, Pia Bredahl Jensen5
1Cardiology Stem Cell Centre, Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
JHLT open
|April 18, 2025
概括
全基脂肪组织衍生性树皮细胞 (ASCs) 是安全的作为肺移植接受者的附加疗法. 虽然在72小时内没有显著减少原发性移植功能障碍 (PGD),但ASC显示有潜力减缓PGD进展.
科学领域:
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
- 移植手术 移植手术
背景情况:
- 主要移植功能障碍 (PGD) 在移植后72小时内影响15-30%的肺移植接受者.
- PGD是新移植肺部的复杂损伤.
研究的目的:
- 作为一种附加疗法,研究所有原脂肪组织衍生的树皮细胞 (ASCs) 的临床安全性和疗效.
- 在接受双重肺移植的患者中评估ASC.
主要方法:
- 一个单中心,双盲,随机的I/II期研究.
- 31名患者在移植后两小时内接受了200万个ASC,1亿个ASC或安慰剂的静脉注射.
- 主要终点:移植后72小时的PGD等级.
主要成果:
- 在ASC组和安慰剂之间72小时后PGD没有显著差异 (P=0.426).
- 与安慰剂相比,联合ASC组在PGD中没有显著差异 (P=0.252).
- 在接受ASC治疗的患者中,从第1天到第3天和第2天到第3天的PGD进展减少 (P=0.034).
结论:
- 肺移植后的静脉ASC输液是安全的.
- 在72小时后,ASC治疗没有显示出PGD的统计学上显著差异.
- ASCs可能有助于减缓肺移植后的PGD进展.
关键词:
脂肪组织衍生的介质细胞 stromal 细胞.异构性疗法是一种全基因疗法.临床试验临床试验是指临床试验的临床试验.移植器官功能障碍 移植器官功能障碍免疫调节 免疫调节肺移植 肺移植 肺移植干细胞是一种干细胞.更多相关视频
11:22Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
17.4K
11:31Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate
Published on: October 31, 2012
15.8K
相关概念视频
01:21Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
01:19Mesenchymal Stem Cells
4.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K